Comparative Pharmacology
Head-to-head clinical analysis: OXTRIPHYLLINE PEDIATRIC versus XOPENEX HFA.
Peer-Reviewed Evidence
Head-to-head clinical analysis: OXTRIPHYLLINE PEDIATRIC versus XOPENEX HFA.
OXTRIPHYLLINE PEDIATRIC vs XOPENEX HFA
Comparing the clinical profiles, pharmacokinetic behaviors, and safety indices of these two therapeutic agents.
Xanthine derivative that inhibits phosphodiesterase, increasing cyclic AMP levels; antagonizes adenosine receptors, leading to bronchodilation, central nervous system stimulation, and positive inotropic effects.
Selective beta-2 adrenergic receptor agonist; relaxes bronchial smooth muscle by increasing intracellular cyclic AMP via activation of adenylyl cyclase.
200 mg orally every 6-8 hours; extended-release: 400-600 mg orally every 12 hours.
2 inhalations (90 mcg each) every 4-6 hours as needed via oral inhalation. Maximum 12 inhalations per 24 hours.
None Documented
None Documented
Neonates: 24-36 hours; Infants 1-6 months: 14-29 hours; Children 6-12 months: 9-18 hours; Children 1-9 years: 3-6 hours; Adults: 7-12 hours. Half-life prolonged in hepatic impairment, CHF, and COPD.
Terminal elimination half-life: 3-4 hours; clinical context: dosing every 4-6 hours for bronchodilation
Renal (70-80% as unchanged drug, 10-15% as metabolites); biliary/fecal (<10%)
Renal: 80-100% as unchanged drug and metabolites; fecal: minimal (<5%)
Category C
Category C
Bronchodilator
Bronchodilator